The Spinal Muscular Atrophy Foundation Announces a Biomarker Panel to Guide SMA Therapeutic Development

NEW YORK, NY – April 3, 2012 – The Spinal Muscular Atrophy (SMA) Foundation announced today the launch of a biomarker assay panel for SMA using Myriad RBM’s Multi-Analyte Profiling (MAP) technology platform. The SMA-MAP panel is designed to evaluate the severity of SMA and disease progression and can be used to assess drug efficacy and shorten the duration of clinical trials for SMA therapeutics.

The SMA Foundation initially provided more than 120 plasma samples from SMA patients collected in the Biomarkers for SMA (BforSMA) clinical study for processing on Myriad RBM’s DiscoveryMAP® 250+ biomarker discovery platform. Analysis of this data revealed a set of candidate biomarkers which were then tested against over 150 longitudinal samples from an SMA natural history study by the Pediatric Neuromuscular Clinical Research Network. A panel of 27 validated biomarkers was selected, and is now being made available to clinical researchers by Myriad RBM as a new product to be called SMA-MAP. Measuring these biomarkers in SMA clinical trials may help researchers to efficiently predict and monitor SMA progression and therapeutic efficacy.

Read More

Rules-Based Medicine Reaches a Significant Milestone in Companion Diagnostic Program With Roche

Milestone Demonstrates Effectiveness of RBM’s Strategic Biomarker Services

AUSTIN, Texas, May 25, 2011 /PRNewswire/ — Rules-Based Medicine (RBM), a global leader in biomarker testing services, and its subsidiary, Psynova Neurotech, has achieved a significant milestone in a companion diagnostic development program with Roche. Using samples from a Roche clinical trial, the RBM DiscoveryMAP® platform, and Psynova’s biomarker database and expertise, a biomarker pattern was identified that has utility in prognosis of disease progression and/or predicting or monitoring the efficacy for a compound in the Roche CNS pipeline. Roche has exercised its option to continue commercial development based on these results, which could result in additional future milestone and royalty payments to RBM/Psynova.

Read More

Rules-Based Medicine Acquires Intellectual Property Assets of Satoris, Inc.

Expansion of IP portfolio to support development and commercialization of novel tests for neurodegenerative diseases

AUSTIN, Texas, May 17, 2011 /PRNewswire/ — Rules-Based Medicine (RBM), a global leader in biomarker testing services, today announced the acquisition of intellectual property assets from Satoris, Inc. The portfolio is based on extensive research to discover biomarkers and biomarker panels for clinical and research use in the areas of Alzheimer’s disease, frontal temporal dementia, Parkinson’s disease, and other conditions that affect the central nervous system.

Read More

Rules-Based Medicine, Inc. (RBM) Partners with Institut Pasteur to Boost Innovation in Translational Research

RBM’s TruCulture® sample collection system will be an integral part of study

AUSTIN, Texas, May 12, 2011 /PRNewswire/ — Rules-Based Medicine, Inc. a leading provider of multiplexed protein biomarker services will be a collaborator on the Institut Pasteur research project Milieu Interieur (the environment within), funded through a LabEx grant from the French government. The project will rely on RBM’s TruCulture® R an innovative in vitro model that preserves physiological cellular interactions, to more accurately describe the complexities of the human immune system.

Read More

Myriad Genetics Announces Agreement to Acquire Rules-Based Medicine

Acquisition Expands Myriad’s Leadership Position in Companion Diagnostics

SALT LAKE CITY and AUSTIN, Texas, April 27, 2011 (GLOBE NEWSWIRE) — Myriad Genetics Inc. (Nasdaq:MYGN) today announced that it has entered into a definitive merger agreement to acquire privately-held Rules-Based Medicine (RBM) of Austin, Texas for $80 million in cash. The deal expands Myriad’s research portfolio into new disease states, including psychiatric disorders, infectious diseases and inflammatory diseases, and adds eight new molecular diagnostic product candidates to Myriad’s already strong pipeline. RBM’s history of strategic alliances with over 20 major pharmaceutical and biotechnology companies, coupled with Myriad’s position in PARP inhibitors and PI3K inhibitors, creates a leading franchise in companion diagnostics. Furthermore, the RBM acquisition provides Myriad with access to patient cohorts for new diagnostic development and is expected to enhance Myriad’s industry-leading DNA and RNA technologies with unparalleled strength in protein discovery and analysis.

Read More

Rules-Based Medicine Launches OncologyMAP® to Advance Cancer-Related Drug and Diagnostic Development

Panel of 101 quantitative biomarker tests selected in partnership with the National Cancer Institute

AUSTIN, Texas, March 24, 2011 /PRNewswire/ — Rules-Based Medicine, Inc. (RBM), a leading provider of innovative biomarker solutions, today formally announced the global launch of OncologyMAP®, a powerful tool developed at the direction of and with funding from the National Cancer Institute. Through quantitative measurement of 101 cancer-related proteins, OncologyMAP® provides researchers with unprecedented data on biological pathways that could hold the key to understanding the molecular basis of cancer. OncologyMAP® was released to a limited number of key customers in October, and RBM has received positive feedback from clients who report valuable results in their studies for drug re-tasking, indication expansion, and patient stratification using this cost-effective, comprehensive testing service.

Read More

SMA Foundation and Rules-Based Medicine Collaborate on Biomarker Panels to Guide SMA Therapeutic Development

NEW YORK, NY AND AUSTIN, TX – January, 2011 – The Spinal Muscular Atrophy (SMA) Foundation and Rules-Based Medicine, Inc. (RBM) announced today that they have reached the first milestone in a program to develop a panel of plasma protein biomarkers for SMA using RBM’s Multi-Analyte Profiling (MAP) technology platform. In this collaboration, RBM will discover and also confirm plasma protein biomarker candidates previously identified from the multicenter Biomarkers for SMA (BforSMA) clinical study sponsored by the SMA Foundation and conducted by BG Medicine. The identification of such biomarkers may help to assess drug efficacy and shorten the duration of clinical trials of SMA therapies.

Read More
1 2 3 4 5 6